Sun Pharma Advanced Research Company Ltd
Pharmaceuticals & Biotechnology | Small Cap
Sun Pharma Advanced Research Company Ltd, operating within the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strong solvency and some positive growth indicators, particularly in operating profit and EPS. However, it struggles with liquidity, efficiency, coverage, financial metrics, and profitability. Revenue and asset growth have declined, and key profitability margins are significantly negative. The company's high solvency score is contrasted by poor liquidity and profitability, suggesting potential challenges in meeting short-term obligations and generating profit from its operations. Overall, while there are areas of strength, significant improvements are needed to ensure long-term financial stability and growth.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio7.20
- Financial Ratio2.00
- Profitability Ratio2.00
- Efficiency Ratio4.00
- Coverage Ratio2.00
- Solvency Ratio10.00
- Liquidity Ratio3.10
- Peer Assessment
- Management AssessmentWeak
- Risk AssessmentWeak
- 1 HourBearish
- 2 HoursNeutral
- 4 HoursBullish
- 1 DayBullish
- 1 WeekBullish
- 1 MonthBullish
Sun Pharma Advanced Research Company Ltd, operating within the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strong solvency and some positive growth indicators, particularly in operating profit and EPS. However, it struggles with liquidity, efficiency, coverage, financial metrics, and profitability. Revenue and asset growth have declined, and key profitability margins are significantly negative. The company's high solvency score is contrasted by poor liquidity and profitability, suggesting potential challenges in meeting short-term obligations and generating profit from its operations. Overall, while there are areas of strength, significant improvements are needed to ensure long-term financial stability and growth.
Overall Valuation Score
P/E RATIO (TTM)
4.98
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
4.97
P/B RATIO
5.76
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
3.79
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
4.46
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹238.09 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company exhibits mixed growth signals. While operating profit and EPS growth are positive, revenue and asset growth have declined. This suggests that while the company is improving its profitability, it struggles to expand its revenue base and asset portfolio. Continued focus on innovation and market expansion is crucial for sustained growth.
| Growth Ratios | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue Growth Rate | -68.2 | -5.26 | 2509.72 | |
| Operating Profit Growth Rate | 87.85 | -19.65 | -595.05 | |
| Earnings Per Share (EPS) Growth | 73.91 | -11.57 | -553.65 | |
| Asset Growth Rate | -37.95 | -34.76 | 546.13 | |
| Net Income Growth Rate | 73.54 | -11.37 | -552.77 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial metrics are generally weak. Negative adjusted and cash EPS indicate unprofitability. A negative book value per share is a significant concern, reflecting potential erosion of shareholder equity. Zero dividend per share also suggests that the company is not returning value to shareholders. These factors highlight the need for improved financial performance.
| Financial Ratios | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | -6.97 | -12.12 | -10.72 | 48.91 |
| Cash Earnings Per Share (Cash EPS) | -6.59 | -11.69 | -10.34 | 48.84 |
| Book Value Per Share | 16 | 3.91 | -6.78 | 41.81 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 14.9 | 26 | 9.8 | 23.5 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability ratios are significantly negative across all metrics, including gross profit margin, ROCE, ROE, ROA, operating margin, and net margin. This indicates severe challenges in generating profit from its operations and efficiently utilizing its capital and assets. Addressing these issues is crucial for improving financial health and sustainability.
| Profitability Ratios | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Profit Margin | -94.56 | -546.05 | -465.28 | 84.57 |
| Return on Capital Employed (ROCE) | -40.72 | -108 | -279 | 164 |
| Return on Equity (ROE) | -43.55 | -309.6 | 116.07 | |
| Return on Assets (ROA) | -25.78 | -78.06 | -96.13 | 73.65 |
| Operating Margin | -89.54 | -528.95 | -448.61 | 85.1 |
| Net Margin | -93.31 | -509.21 | -476.39 | 82.65 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency metrics present a mixed picture. The fixed asset and capital turnover ratios are low, indicating inefficient use of assets. The receivables turnover is moderate, but the receivable days suggest some delays in collecting payments. Zero days sales in inventory suggest efficient inventory management. These factors collectively impact the company's operational efficiency.
| Efficiency Ratios | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 2.25 | 0.7 | 0.73 | 11.97 |
| Inventory Turnover Ratio | N/A | N/A | N/A | N/A |
| Receivables Turnover Ratio | 7.3 | 3.1 | 4.5 | 156.58 |
| Days Sales in Inventory Ratio | N/A | N/A | N/A | N/A |
| Receivable Days | 50 | 117.74 | 81.11 | 2.33 |
| Capital Turnover Ratio | 0.45 | 0.55 | -0.68 | 1.4 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios are weak, with a negative interest coverage ratio and zero equity dividend coverage. This indicates difficulties in meeting interest obligations and returning value to shareholders through dividends. Addressing these issues is vital for improving investor confidence and financial stability.
| Coverage Ratios | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Interest Coverage Ratio | -26.88 | -192.5 | -37.11 | 46.68 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency position is strong, characterized by a negative debt ratio and debt-to-equity ratio, coupled with a high equity ratio. This indicates that the company relies more on equity than debt for financing. A lower debt to asset ratio also suggests strong solvency. This financial structure provides a stable foundation for long-term sustainability and growth.
| Solvency Ratios | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debt Ratio | 0.03 | 0.1 | -1.05 | 0 |
| Debt to Equity Ratio | 0.03 | 0.11 | -0.51 | 0 |
| Equity Ratio | 0.97 | 0.9 | 2.05 | 1 |
| Debt To Asset Ratio | 0.02 | 0.03 | 0.33 | 0 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is concerning. While a slightly positive quick ratio offers a small cushion, low current and cash ratios suggest potential difficulties in meeting short-term obligations. Negative operating cash flow further strains liquidity. The industry demands readily available cash for operations and research, making these low ratios a significant challenge.
| Liquidity Ratios | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Current Ratio | 1.34 | 0.97 | 0.41 | 2.43 |
| Quick Ratio | 1.34 | 0.97 | 0.41 | 2.43 |
| Cash Ratio | 0.37 | 0.41 | 0 | 0 |
| Operating Cash Flow Ratio | -0.23 | -1.14 | -0.81 | -0.29 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Amrutanjan Health Care Ltd | 8.25 | 77.37 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 2 | FDC Ltd | 7.64 | 22.52 | Neutral | 346.00 | 17.56 | 281.00 |
| 3 | Supriya Lifescience Ltd | 7.46 | 35.88 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 4 | Aarti Pharmalabs Ltd | 7.46 | 35.90 | Neutral | 369.00 | 19.44 | 175.00 |
| 5 | Innova Captab Ltd | 7.36 | 38.55 | Overvalued | 243.00 | 14.63 | 141.00 |
| 6 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 37.30 | Overvalued | 522.00 | 7.09 | 256.00 |
| 7 | Hikal Ltd | 7.13 | -51.71 | Neutral | 220.00 | -3.95 | -49.00 |
| 8 | RPG Life Sciences Ltd | 7.12 | 32.70 | Neutral | 147.00 | 69.64 | 115.00 |
| 9 | Morepen Laboratories Ltd | 7.12 | 28.61 | Neutral | 126.00 | 1.21 | 96.00 |
| 10 | Alembic Ltd | 7.06 | 7.28 | Undervalued | 90.00 | 4.85 | 317.00 |
| 11 | SMS Pharmaceuticals Ltd | 5.94 | 34.77 | Neutral | 171.00 | 9.35 | 102.00 |
| 12 | Shilpa Medicare Ltd | 5.94 | 44.32 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 13 | Gufic BioSciences Ltd | 5.49 | 55.51 | Neutral | 151.00 | 6.30 | 64.00 |
| 14 | Dishman Carbogen Amcis Ltd | 5.38 | 27.45 | Neutral | 566.00 | -2.45 | 97.00 |
| 15 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 27.76 | Undervalued | 269.00 | 4.69 | 138.00 |
| 16 | Indoco Remedies Ltd | 5.26 | -22.79 | Neutral | 142.00 | -0.61 | -99.00 |
| 17 | Aarti Drugs Ltd | 5.07 | 17.34 | Undervalued | 309.00 | 18.54 | 195.00 |
| 18 | Orchid Pharma Ltd | 4.85 | 241.74 | Neutral | 41.00 | 8.91 | 21.00 |
| 19 | Sequent Scientific Ltd | 4.61 | 293.05 | Overvalued | 162.00 | 0.63 | 32.00 |
| 20 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.97 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 21 | Solara Active Pharma Sciences Ltd | 4.34 | -274.68 | Neutral | 187.00 | -1.50 | -7.00 |
| 22 | Zota Health Care Ltd | 3.97 | -61.25 | Neutral | 19.00 | 8.06 | -74.00 |
The management assessment for Sun Pharma Advanced Research Company Ltd is flagged as Red, indicating significant concerns. The company exhibits negative profitability, reflected in poor OPM and Net Profit margins. Sales have declined substantially, and there's an increasing reliance on borrowings. Returns on Capital Employed (ROCE) and Equity (ROE) are negative, signaling inefficient capital use and poor returns to shareholders. While promoter holding remains high, declining FII interest and a high number of shareholders could indicate a lack of institutional confidence and increased retail interest due to speculative reasons. Overall, the financial performance and capital efficiency metrics suggest significant challenges in management effectiveness.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 65.68% | Shows continued promoter confidence |
| CONS | Sales Growth | -5.00% | Indicates declining revenue |
| OPM | -450% | Reflects poor operational efficiency | |
| ROCE | -279% | Indicates inefficient use of capital |
Financial Performance & Growth
Sun Pharma Advanced Research Company Ltd demonstrates poor financial performance and growth. The company's sales have significantly declined, with a Sales Growth of -68.36% in Mar 2024 and -5.00% in Mar 2025. The operating profit margin (OPM) is deeply negative, standing at -532% in Mar 2024 and -450% in Mar 2025. Net profits are also negative, with values of -387 Cr in Mar 2024 and -343 Cr in Mar 2025. The reliance on other income is minimal, failing to offset the substantial operating losses. This data indicates severe challenges in revenue generation and cost management.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Sales (Cr) | 239 | 76 | 72 |
| Sales Growth (%) | -68.36% | -5.00% | |
| OPM (%) | -90% | -532% | -450% |
| Net Profit (Cr) | -223 | -387 | -343 |
Capital Efficiency & Returns
Capital efficiency and returns for Sun Pharma Advanced Research Company Ltd are weak. The Return on Capital Employed (ROCE) is significantly negative, with -108% in Mar 2024 and -279% in Mar 2025, indicating inefficient capital utilization.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| ROCE (%) | -108% | -279% |
Financial Health & Prudence
The financial health and prudence of Sun Pharma Advanced Research Company Ltd is poor. Borrowings have substantially increased from 16 Cr in Mar 2023 to 61 Cr in Mar 2024 and further to 269 Cr in Mar 2025. This increase in debt raises concerns about the company's financial stability and its ability to meet its obligations. The company does not pay dividends, indicated by a Dividend Payout % of 0% consistently over the years.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Borrowings (Cr) | 16 | 61 | 269 |
| Dividend Payout (%) | 0% | 0% | 0% |
Shareholding & Ownership Structure
The shareholding and ownership structure of Sun Pharma Advanced Research Company Ltd presents a mixed picture. Promoter holding is high at 65.68%, indicating continued promoter confidence. However, FII interest has decreased from 3.64% in Mar 2023 to 1.45% in Mar 2025. DII interest remains low. The number of shareholders has increased significantly from 98,777 in Mar 2023 to 142,864 in Mar 2025.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Promoter Holding (%) | 65.68% | 65.68% | 65.68% |
| FII Holding (%) | 3.64% | 3.24% | 1.45% |
| DII Holding (%) | 0.63% | 0.67% | 1.13% |
| No. of Shareholders | 98,777 | 102,743 | 142,864 |
The risk assessment for Sun Pharma Advanced Research Company Ltd is flagged as Red due to several critical factors. The company faces significant operational challenges, reflected in its negative profitability and declining sales. Increasing borrowings and negative ROCE indicate heightened financial risk. The inconsistency in quarterly sales and profit growth, alongside a deeply negative operating profit margin, further exacerbates these risks. Declining FII interest adds to the negative outlook. Overall, the combination of poor financials and operational inefficiencies indicates a high-risk profile.
Accounting quality red flags
No specific accounting red flags are apparent from the provided data.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10240.92Bearish
- SMA 20239.61Bearish
- SMA 50229.43Bullish
- EMA 10239.59Bearish
- EMA 20238.35Bearish
- EMA 50231.25Bullish
- DEMA 10239.82Bearish
- DEMA 20242.14Bearish
- DEMA 50242.09Bearish
- TEMA 10238.81Bearish
- TEMA 20240.27Bearish
- TEMA 50244.44Bearish
- MACD2.48Bearish
- ADX53.29Strong Trend
- IndicatorValueSignal
- RSI52.87Neutral
- CCI-83.63Neutral
- ROC 9-3.13Bearish
- ROC 14-0.66Bearish
- ROC 252.19Bullish
- Stoch K29.69Neutral
- Stoch D31.61Neutral
- IndicatorValueSignal
- BB Upper244.50Neutral
- BB Middle239.61Neutral
- BB Lower234.72Neutral
- ATR4.23Low Volatility
- IndicatorValueSignal
- MFI60.51Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10238.94Bearish
- SMA 20236.46Bullish
- SMA 50221.06Bullish
- EMA 10238.32Bearish
- EMA 20234.54Bullish
- EMA 50223.85Bullish
- DEMA 10240.69Bearish
- DEMA 20242.49Bearish
- DEMA 50239.18Bearish
- TEMA 10238.95Bearish
- TEMA 20242.76Bearish
- TEMA 50240.78Bearish
- MACD5.62Bearish
- ADX50.75Strong Trend
- IndicatorValueSignal
- RSI62.38Neutral
- CCI19.03Neutral
- ROC 9-0.59Bearish
- ROC 141.82Bullish
- ROC 2516.59Bullish
- Stoch K33.97Neutral
- Stoch D41.33Neutral
- IndicatorValueSignal
- BB Upper245.28Neutral
- BB Middle236.46Neutral
- BB Lower227.65Neutral
- ATR5.44Low Volatility
- IndicatorValueSignal
- MFI69.23Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 10236.56Bullish
- SMA 20223.44Bullish
- SMA 50209.43Bullish
- EMA 10234.59Bullish
- EMA 20227.15Bullish
- EMA 50209.17Bullish
- DEMA 10241.94Bearish
- DEMA 20239.84Bearish
- DEMA 50236.62Bullish
- TEMA 10241.96Bearish
- TEMA 20241.75Bearish
- TEMA 50N/AN/A
- MACD9.67Bullish
- ADX41.09Strong Trend
- IndicatorValueSignal
- RSI65.65Neutral
- CCI77.02Neutral
- ROC 93.43Bullish
- ROC 1415.77Bullish
- ROC 2519.77Bullish
- Stoch K73.58Neutral
- Stoch D77.39Neutral
- IndicatorValueSignal
- BB Upper252.26Neutral
- BB Middle223.44Neutral
- BB Lower194.62Neutral
- ATR8.60Low Volatility
- IndicatorValueSignal
- MFI82.55Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10220.89Bullish
- SMA 20216.16Bullish
- SMA 50178.26Bullish
- SMA 100152.50Bullish
- SMA 200144.54Bullish
- EMA 10225.33Bullish
- EMA 20212.92Bullish
- EMA 50186.30Bullish
- EMA 100166.31Bullish
- EMA 200156.62Bullish
- DEMA 10237.97Bullish
- DEMA 20234.74Bullish
- DEMA 50217.68Bullish
- DEMA 100189.61Bullish
- DEMA 200158.53Bullish
- TEMA 10240.80Bullish
- TEMA 20237.52Bullish
- TEMA 50234.22Bullish
- TEMA 100211.47Bullish
- TEMA 200180.11Bullish
- MACD16.31Bullish
- ADX39.04Strong Trend
- IndicatorValueSignal
- RSI70.81Overbought
- CCI142.55Overbought
- ROC 1414.31Bullish
- ROC 2543.75Bullish
- Stoch K89.33Overbought
- Stoch D81.23Overbought
- IndicatorValueSignal
- BB Upper247.96Neutral
- BB Middle216.16Neutral
- BB Lower184.35Neutral
- ATR13.56High Volatility
- IndicatorValueSignal
- MFI71.94Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 20151.81Bullish
- SMA 50144.82Bullish
- EMA 20165.07Bullish
- EMA 50155.61Bullish
- DEMA 20187.08Bullish
- DEMA 50149.16Bullish
- TEMA 20206.45Bullish
- TEMA 50166.99Bullish
- MACD19.23Bullish
- ADX43.15Strong Trend
- IndicatorValueSignal
- RSI69.87Neutral
- CCI311.69Overbought
- ROC 1480.51Bullish
- ROC 2555.58Bullish
- Stoch K76.90Neutral
- Stoch D79.97Neutral
- IndicatorValueSignal
- BB Upper220.80Overbought
- BB Middle151.81Neutral
- BB Lower82.82Neutral
- ATR22.56High Volatility
- IndicatorValueSignal
- MFI90.33Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 6142.94Bullish
- SMA 12142.49Bullish
- SMA 24166.72Bullish
- EMA 6155.11Bullish
- EMA 12152.43Bullish
- EMA 24168.27Bullish
- DEMA 6168.52Bullish
- DEMA 12143.18Bullish
- DEMA 24137.45Bullish
- TEMA 6184.33Bullish
- TEMA 12157.02Bullish
- TEMA 24129.12Bullish
- MACD-31.40Bullish
- ADX11.70Weak Trend
- IndicatorValueSignal
- RSI50.87Neutral
- CCI-12.32Neutral
- ROC 25-8.69Bearish
- ROC 50-28.57Bearish
- Stoch K15.72Oversold
- Stoch D12.14Oversold
- IndicatorValueSignal
- BB Upper219.90Neutral
- BB Middle154.71Neutral
- BB Lower89.51Neutral
- ATR43.61High Volatility
- IndicatorValueSignal
- MFI93.17Overbought